Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

News

OUBT logo, BioEscalator logo, Arctoris logo & Oxford Nanopore Technologies

BioEscalator Sponsors Oxford Catalyse Programme 2022

The BioEscalator is sponsoring a prize for the Biohackaton 2022, where teams created during the Oxford Catalyse 2022 programme will pitch their final business plans to a panel of judges.

A photo of the BioEscalator's new laboratory space. Rows of bench space with a glass panel wall reflecting the outside behind them.

BioEscalator Opens New Laboratory

In December 2021, the BioEscalator opened a brand-new 137m2 laboratory, providing much-needed additional incubator space for Oxford-based start-ups.

A team hand stack (people's hands placed on top of each other) to the left with the Bioarchitech and SIGA Human Bioarmor logos to the right.

SIGA Announces Preclinical Oncology Research Collaboration with Bioarchitech

The research collaboration will investigate TPOXX® (tecovirimat) in combination with Bioarchitech’s proprietary vaccinia-based immunotherapy platform in preclinical studies.

Image of Laurie Keating and a quote from her: "I am thrilled to be joining PepGen as the new Chair of the Board of Directors. I look forward to guiding the company’s development and supporting the leadership team as they seek to transform the lives of patients with innovative new treatment options for severe neuromuscular and neurologic diseases"

PepGen Appoints Laurie Keating as Chair of Board of Directors

Keating brings strong experience as a life science executive and Board member.

Kyttaro and OUI logos, each in a jigsaw piece, slotting together.

Kyttaro Announces an Exclusive Worldwide Licensing Agreement with Oxford University Innovation

Kyttaro plans to develop a peptide technology platform to create novel biologic therapeutics addressing various causes of inflammation, a major mechanism underlying cardiovascular disease.

Two hands hold a liver in the middle of the image. The Ochre Bio logo is on the top right of the image. The British Liver Trust logo is on the bottom left of the image.

Ochre Bio Enters into Charitable Donation Agreement with British Liver Trust

The two companies share the same goals, to improve the lives of those dealing with liver disease.

Image of Isami J. Salcedo and Sonia Bracegirdle with the PepGen logo

PepGen Appoints Vice President of Program Management and Promotes Sonia Bracegirdle to Senior Vice President, Strategy & Operations

Dr Bracegirdle will lead the expanded PepGen Strategy and Operations team. Isami J. Salcedo, experienced biotechnology operations and programme management professional, joins as Vice President of Program Management.

Exact Sciences' logo and The Oxford Science Park's logo. The Oxford Science Park's Sherard building is in the background.

Exact Sciences Innovation Graduates to The Oxford Science Park

Helping people get the answers they need to make more informed decisions across the cancer continuum.

Gene Linked to Doubling the Risk of Death due to COVID-19 Identified Using Technology Exclusively Licensed to Nucleome Therapeutics

The technology used to identify this gene has been exclusively licensed to Nucleome, highlighting the competitive advantage of Nucleome’s platform in the discovery of genetic targets for innovative precision medicine development.

The top half of the image is the Exogene logo on a pastel rainbow background. The lower half of the image is the KQ Labs logo and the Frances Crick Institute logo on a black background.

Exogene Selected for KQ Labs Accelerator Programme

KQ Labs is a five-month accelerator programme for exciting early-stage startups using data as a core part of their business model to improve human health, run by the Francis Crick Institute and funded by LifeArc.

A quote from Noel Donnelly, newly appointed Chief Financial Officer at PepGen: “It’s an honour to join the team as CFO and I look forward to continuing the forward momentum needed to make a lasting impact on people living with neuromuscular diseases and their families.”

PepGen Appoints Noel Donnelly as Chief Financial Officer

The new appointment represents a continued expansion of PepGen’s leadership team in Boston following successful $112.5 million Series B financing.

Ochre Bio Shortlisted as an OBN Awards 2021 Finalist in the BioSeed ‘One to Watch’ Category

Recipients of the OBN Awards are considered to have made an outstanding and valuable contribution to their field, which is why Ochre Bio is thrilled to have made the cut at this early stage of its life.

BioEscalator's 3rd anniversary

Oxford BioEscalator Celebrates Three Years of Innovation

The BioEscalator concept was born out of a shared need by academic researchers and their bioscience company collaborators for start-up incubator space close to academic labs. The vision was to develop a leading international centre for innovative bioscience with the potential to make a significant impact on healthcare. The incubator provides spin-outs and start-ups with laboratory and business support, enabling them to grow into leading bioscience ventures.

Images of Dr Jane Larkindale and Heidi Henson

PepGen Announces New Additions to Leadership Team and Board of Directors

Heidi Henson will join PepGen’s Board of Directors. The company also announced the promotion of Jane Larkindale, PhD, to Vice President of Clinical Science.

A row of bags of money, growing in size from left to right. The bags have plants growing out of them, also growing in size from left to right.

BioEscalator Companies Attract Record Funding as Investors Switch-on to Biotech

Despite the disruption caused by the pandemic, BioEscalator companies attracted a record high of £1.2B investment. This is part of a trend that saw investors attracted to the resilience displayed by the life science industry to the pandemic relative to other sectors.

Coins are scattered and stacked behind a graph trending upwards. The PepGen logo is in the top left-hand corner of the image.

PepGen Announces Closing of $112.5M Crossover Financing to Advance Transformative Therapies for Neuromuscular Diseases

Proceeds to support expansion and advancement of PepGen’s pipeline of Enhanced Delivery Oligonucleotide (EDO) therapies for neuromuscular and neurologic diseases.

Theolytics logo

Theolytics Graduates From the BioEscalator

After a highly successful start, Theolytics is ready for the next step in its journey and is moving to The Oxford Science Park. The company will be the first tenant moving into the newly refurbished Sherard Building.

The Medimab logo and the University Hospitals Birmingham logo are side by side on a grey background. Underneath is an image of scattered white dots connected with white lines on a navy blue background.

MediMabBio Establishes a Bridgehead for the Development of Immuno-oncology Drugs in the UK

MediMabBio has started global clinical trials of its flagship pipeline. After securing R&D funding through a Series A round earlier this year, it will collaborate with a UK clinical trial institution to conduct joint research to develop a treatment for liver cancer.

Ochre Bio Logo

Ochre Bio Raises $9.6M to Advance RNA Therapies for Liver Diseases

The funding will be used to advance the development of Ochre Bio’s RNA therapies and expand its deep phenotyping platform to identify and validate new liver targets.

To the left, the OBN Awards logo and the Alchemab Therapeutics logo are on a deep purple background. To the right, there is an image of London overlooking the River Thames. Glitter is falling from the sky.

Alchemab Therapeutics wins Best Start-up Biotech Company at the OBN Awards 2020

Alchemab Therapeutics, a former resident company at Oxford's BioEscalator, has won Best Start-up Biotech Company at the prestigious 2020 OBN Awards, presented on Friday 11 June at the Royal Lancaster in London.

Load More